LANCET ONCOLOGY
-
- Visão geral
-
- Metrics
-
- Identidade
-
- Ver todos
-
Visão geral
Qualis
código do país
tipo
publicação venue de
-
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
24:273-285.
2023-01-01
-
Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries.
24:22-32.
2023-01-01
-
Carcinogenicity of aspartame, methyleugenol, and isoeugenol.
ahead:ahead.
2023-01-01
-
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.
24:e172-e185.
2023-01-01
-
Radiotherapy resources in Brazil (RT2030): a comprehensive analysis and projections for 2030.
24:903-912.
2023-01-01
-
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
23:e334-e347.
2022-01-01
-
A comprehensive framework for early-onset colorectal cancer research.
23:e116-e128.
2022-01-01
-
Call for action: expanding global access to hereditary cancer genetic testing.
23:1124-1126.
2022-01-01
-
Carcinogenicity of cobalt, antimony compounds, and weapons-grade tungsten alloy.
23:577-578.
2022-01-01
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
23:e374-e384.
2022-01-01
-
European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
23:e21-e31.
2022-01-01
-
High hopes for a healthier Brazil with Lula's third mandate.
23:e533.
2022-01-01
-
IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship.
23:e103.
2022-01-01
-
Identifying areas at risk of endometrial cancer increase in Latin America: development of a geospatial model.
23:S41.
2022-01-01
-
Oral lichen planus and the Thr102Cys polymorphism of HTR2A: a pilot case-control study.
23:S35.
2022-01-01
-
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
23:1.
2022-01-01
-
Prioritising locations for radiotherapy equipment in Brazil: a cross-sectional, population-based study and development of a LINAC shortage index.
23:531-539.
2022-01-01
-
Pulling the investment levers on implementation research in oncology.
23:451-452.
2022-01-01
-
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
23:465-478.
2022-01-01
-
A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease.
X:X-XX.
2021-01-01
-
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
22:1126-1138.
2021-01-01
-
Cancer and COVID-19 vaccines: a complex global picture.
22:749-751.
2021-01-01
-
Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward.
22:e474-e487.
2021-01-01
-
Carcinogenicity of 1,1,1-trichloroethane and four other industrial chemicals.
22:1661-1662.
2021-01-01
-
Carcinogenicity of gentian violet, leucogentian violet, malachite green, leucomalachite green, and CI Direct Blue 218.
22:585-586.
2021-01-01
-
Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study.
22:43-50.
2021-01-01
-
Copanlisib plus rituximab versus placebo rituximab in patients with relapse indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
22:1-12.
2021-01-01
-
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
11:1507-1517.
2021-01-01
-
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
22:142-154.
2021-01-01
-
Gestational trophoblastic neoplasia: one size does not fit all - Authors' reply.
22:e421.
2021-01-01
-
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
22:620-631.
2021-01-01
-
Partial breast irradiation with intraoperative radiotherapy in the ELIOT trial.
22:e297.
2021-01-01
-
Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?.
22:1365-1366.
2021-01-01
-
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
22:931-945.
2021-01-01
-
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
22:512-524.
2021-01-01
-
Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean.
22:e488-e500.
2021-01-01
-
Predictions for single-agent resistance in FIGO score 5 or 6 gestationaç trophoblastic neoplasia: a multicentre, retrospective, cohort study.
xx:xx.
2021-01-01
-
Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study.
1:1-11.
2021-01-01
-
Priorities for the global advancement of care for older adults with cancer: an update of the International Society of Geriatric Oncology Priorities Initiative.
22:e29-e36.
2021-01-01
-
Secondary cytoreduction for relapsed ovarian cancer.
22:e231.
2021-01-01
-
The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
21:1-52.
2021-01-01
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
22:e105-e118.
2021-01-01
-
Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study.
22:1014-1022.
2021-01-01
-
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
x:x.
2020-01-01
-
Carcinogenicity of acrolein, crotonaldehyde, and arecoline.
12:1.
2020-01-01
-
Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines.
21:e444-e451.
2020-01-01
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
21:1574-1588.
2020-01-01
-
Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America.
21:753-755.
2020-01-01
-
Head and neck surgery recommendations during the COVID-19 pandemic.
21:e416.
2020-01-01
-
How current assay approval policies are leading to unintended imprecision medicine.
21:1399-1401.
2020-01-01
-
Knowledge gaps in oncoplastic breast surgery.
21:e375-e385.
2020-01-01
-
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
1:1-30.
2020-01-01
-
Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.
21:851-860.
2020-01-01
-
Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus.
21:e350-e359.
2020-01-01
-
Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic.
00:00.
2020-01-01
-
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
21:1630-1642.
2020-01-01
-
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
21:1188-1200.
2020-01-01
tem uma área de assunto
publisher
is open access
-
False
invalid format
is in DOAJ
-
False
invalid format
Metrics
2 year mean citedness
H index
i10 index
Identidade
ISSN-L
openalex identifier
-
https://openalex.org/S116900674
International Standard Serial Number (ISSN)